Skip to content

Transdermal Peptide Delivery — Microneedle, Iontophoretic, and Physical Enhancement Technologies

Executive Summary

Transdermal drug delivery offers distinct advantages over both oral and injectable routes: avoidance of first-pass hepatic metabolism, sustained and controlled drug input, simplified dosing regimens, and the ability to terminate delivery by patch removal. For therapeutic peptides—which are uniformly degraded in the gastrointestinal tract and require frequent injections—the transdermal route represents a particularly attractive alternative. However, the stratum corneum, the outermost layer of human skin, presents a formidable barrier that excludes virtually all molecules larger than approximately 500 Da. Since most therapeutic peptides exceed this threshold by a substantial margin, effective transdermal peptide delivery requires active technologies that transiently disrupt or bypass the stratum corneum barrier.

This article provides a comprehensive scientific examination of the technologies enabling transdermal peptide delivery: microneedle arrays (solid, coated, dissolving, and hollow), iontophoresis, sonophoresis, thermal ablation, and chemical penetration enhancers. We explore the mechanistic basis of each technology, review key clinical and preclinical evidence, analyze peptide-specific formulation challenges, and assess the current and future landscape of transdermal peptide therapeutics.

Scientific Summary

Transdermal peptide delivery uses active technologies — microneedles (solid, coated, dissolving, hollow), iontophoresis, sonophoresis, thermal ablation, and chemical enhancers — to move peptides past the stratum corneum, whose ~500 Da permeability cutoff excludes essentially all peptides from passive passage. The topic matters because needle-free, self-administered delivery would remove a major burden of chronic peptide therapy and open vaccine and hormone applications. What is established: microneedles reach defined epidermal depths with minimal pain and have carried peptides and vaccines through clinical trials; iontophoresis drives charged peptides with controllable current; peptide stability and dose capacity — not skin physics alone — bound what each platform can deliver. What remains uncertain: no transdermal peptide therapeutic holds broad marketing authorization yet, and dose ceilings for microneedle formats remain below the needs of many peptides.

Evidence Overview

Evidence type What exists — and what does not
Human studies Modest and product-specific — clinical trials exist for PTH(1-34) coated microneedles, influenza vaccine patches, intradermal insulin, and iontophoretic leuprolide; no broad approval has followed yet.
Animal studies Dominant for most platforms — insulin, calcitonin, and heparin studies in rodents and pigs underpin sonophoresis, solid microneedle, and ablation approaches.
In vitro Standard development layer — skin permeation studies (Franz cell) quantify flux enhancement and inform device parameters.
Mechanistic Well characterized — cavitation, electromigration/electroosmosis, lipid disruption, and microchannel formation are understood mechanisms.
Preclinical Broad — device-plus-peptide combinations have been demonstrated preclinically across many peptides; the funnel to approved products is narrow.
Review literature Extensive — the field is well reviewed, including candid assessments of why translation has lagged.

Background

The Skin as a Delivery Barrier

Human skin is the body's largest organ, and its primary physiological function is protective. From a drug delivery perspective, the skin can be conceptualized as a multi-layered composite barrier. The viable epidermis (50–100 μm), composed of keratinocytes at various stages of differentiation, is metabolically active and contains enzymatic activity that can degrade peptides. The dermis (1–4 mm), composed of collagen, elastin, and glycosaminoglycans, is highly vascularized; peptides reaching the dermis are rapidly absorbed into the systemic circulation through the dermal capillary network.

However, it is the stratum corneum (10–20 μm)—often described as a "brick and mortar" structure—that represents the rate-limiting barrier. Corneocytes (the "bricks") are flattened, anucleate cells filled with cross-linked keratin filaments and surrounded by a cornified cell envelope. These cells are embedded in a continuous lipid matrix (the "mortar") composed of ceramides (~50%), cholesterol (~25%), and free fatty acids (~15%) organized into highly ordered lamellar bilayers. This lipid matrix creates a tortuous intercellular pathway that lipid-soluble molecules must navigate, while the corneocyte interior provides a proteinaceous pathway for hydrophilic molecules.

The effective permeability of the stratum corneum is inversely proportional to molecular weight and hydrogen bonding capacity. The "500-Dalton rule" describes the empirical observation that molecules larger than approximately 500 Da exhibit negligible passive transdermal flux. Most therapeutic peptides, with molecular weights ranging from 500 to 5,000 Da, numerous hydrogen bond donors and acceptors, and high aqueous solubility, fall well beyond this threshold. Without active enhancement technologies, transdermal peptide delivery is not feasible.

Historical Development of Transdermal Peptide Delivery

The concept of delivering peptides through the skin emerged in the 1970s and 1980s with the development of iontophoresis and sonophoresis as active enhancement techniques. Early proof-of-concept studies demonstrated that iontophoretic current could drive charged peptides through the skin, albeit at modest flux rates. The 1990s saw the emergence of microneedle technology, first described in a seminal 1998 paper by Henry and colleagues at the Georgia Institute of Technology, which demonstrated that arrays of solid silicon microneedles could create microchannels through the stratum corneum for enhanced drug permeability.

The past two decades have witnessed an explosion of innovation in transdermal peptide delivery. Microneedle technology has matured from academic prototypes to commercial products, with dozens of microneedle-based systems in clinical development. Iontophoretic peptide delivery has achieved regulatory approval for several products. And the convergence of multiple enhancement modalities—microneedle pretreatment combined with iontophoretic driving, for example—has opened new possibilities for achieving therapeutic transdermal peptide delivery.

Microneedle Technologies

Microneedles are microscopic needle-like structures, typically 50–900 μm in height, that penetrate the stratum corneum and viable epidermis without reaching the dermal nerve endings and blood vessels. This depth selectivity—sufficient to breach the barrier but insufficient to cause pain or bleeding—is the defining characteristic of microneedle technology.

Solid Microneedles

Solid microneedles function as pretreatment devices that create transient aqueous microchannels through the stratum corneum. After microneedle application and removal, a conventional drug formulation (patch, cream, gel, or solution) is applied to the microporated skin, and drug molecules diffuse through the created channels into the viable epidermis and dermis.

Fabrication and Materials: Solid microneedles have been fabricated from silicon (using microfabrication techniques derived from the semiconductor industry), metals (stainless steel, titanium, nickel through laser cutting and electroplating), ceramics (alumina), and polymers (polycarbonate, polymethyl methacrylate, polylactic acid through micromolding and hot embossing). Silicon microneedles offer precise geometric control and high aspect ratios but are brittle and can fracture in tissue—a significant safety concern. Metal microneedles offer superior mechanical strength and are less prone to fracture. Polymer microneedles combine adequate mechanical properties with low cost and biocompatibility.

Mechanism of Action: Solid microneedle insertion creates microchannels approximately 10–100 μm in diameter through the stratum corneum. The number, density, and geometry of microchannels determine the effective permeability enhancement. Typical microneedle arrays contain 100–1,000 microneedles per cm², with enhancement factors (ratio of treated to untreated permeability) ranging from 10 to 10,000 depending on the drug and microneedle geometry. Microchannel lifetime—the duration for which created channels remain patent—is typically 24–72 hours, dictated by the rate of epidermal turnover and wound healing responses.

Clinical Evidence for Peptides: Solid microneedle pretreatment followed by peptide application has been investigated for insulin, parathyroid hormone (PTH), calcitonin, desmopressin, and several vaccine antigens. Microneedle-pretreated skin has demonstrated insulin delivery producing pharmacodynamic effects comparable to subcutaneous injection in preclinical and early clinical studies. PTH(1-34) delivery through microneedle-treated skin in clinical studies has produced pharmacokinetic profiles similar to subcutaneous injection, with rapid absorption (Tmax ~30 minutes) and appropriate elimination kinetics.

Limitations: Solid microneedle pretreatment requires a two-step administration process (microneedle application followed by drug application), which is less convenient than integrated approaches. The quantity of drug that can be delivered is limited by the drug loading capacity of the formulation applied to the microporated skin and the finite lifetime of the microchannels. For peptides requiring milligrams of drug per dose, achieving sufficient flux through a practical skin area may be challenging.

Coated Microneedles

Coated microneedles integrate drug coating onto the surface of solid microneedles. Upon insertion into the skin, the coating dissolves in the interstitial fluid of the viable epidermis, releasing the drug into the tissue. This approach eliminates the separate drug application step required with solid microneedles.

Coating Technologies: The challenge of coating microneedles lies in depositing a uniform, adherent drug layer on micrometer-scale structures without compromising insertion capability. Technologies employed include dip coating (immersion in concentrated drug solution followed by drying), spray coating (aerosolized drug solution deposition), inkjet printing (precision deposition of picoliter droplets), and electrohydrodynamic atomization. Coating thicknesses are typically 1–50 μm, limiting the drug payload to approximately 0.1–1 mg per array—adequate for potent peptides with microgram-to-low-milligram doses.

Peptide-Specific Considerations: Peptide coatings must be formulated to rapidly dissolve in the interstitial fluid (typically within 1–5 minutes of insertion), maintain peptide structural integrity during the coating and drying process, and avoid peptide aggregation or fibrillation that could compromise both delivery and safety. Excipients including trehalose, sucrose, and other glass-forming sugars are commonly incorporated to stabilize peptides during the drying process. Surfactants (polysorbates, poloxamers) can improve coating uniformity and wetting.

Clinical Evidence: Coated microneedle patches delivering parathyroid hormone (PTH 1-34) for osteoporosis have been evaluated in clinical studies. Zosano Pharma (acquired by Elixir Medical) developed the ZP-PTH microneedle patch system, which demonstrated rapid PTH delivery with pharmacokinetics similar to subcutaneous injection in Phase III clinical trials. Coated microneedles for influenza and other vaccine antigens have been extensively investigated, with several candidates in late-stage clinical development.

Dissolving Microneedles

Dissolving microneedles are fabricated entirely from water-soluble, biodegradable polymers or sugars in which the drug is incorporated throughout the microneedle matrix. Upon insertion into the skin, the microneedle material dissolves in the interstitial fluid, releasing the encapsulated drug. Unlike coated microneedles, dissolving microneedles completely dissolve, leaving no sharps waste and eliminating the risk of reuse.

Matrix Materials: Common dissolving microneedle matrix materials include hyaluronic acid, carboxymethylcellulose, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), dextran, chondroitin sulfate, maltose, and sucrose. Hyaluronic acid is particularly attractive due to its biocompatibility, biodegradability, and intrinsic viscoelastic properties that facilitate microneedle fabrication by micromolding. The molecular weight and concentration of the matrix polymer influence mechanical properties, dissolution rate, and drug release kinetics.

Fabrication: Dissolving microneedles are typically fabricated by micromolding: a concentrated polymer-drug solution is cast into a mold (often polydimethylsiloxane, PDMS) bearing inverse microneedle cavities, followed by drying or curing. Two-step molding processes can create layered structures with drug concentrated in the microneedle tips and drug-free base layers, maximizing delivery efficiency. Centrifugation and vacuum application facilitate filling of the mold cavities.

Peptide-Specific Advantages and Challenges: Dissolving microneedles offer several peptide-specific advantages: aqueous processing conditions that avoid organic solvents potentially denaturing to peptides; the ability to incorporate stabilizing excipients directly into the microneedle matrix; and complete dissolution that eliminates concerns about needle tip fracture. However, the drying or curing step can expose peptides to stresses (elevated temperature, dehydration, pH changes) that may induce aggregation or degradation. The limited mechanical strength of some dissolving matrices, particularly at high drug loadings, can compromise insertion capability.

Clinical Evidence: Dissolving microneedle patches for influenza vaccination (using hemagglutinin antigen) have completed Phase I clinical trials demonstrating immunogenicity comparable to intramuscular injection with favorable safety profiles. Dissolving microneedles for insulin delivery have demonstrated rapid systemic absorption with pharmacodynamics approaching subcutaneous injection in preclinical models, though clinical translation remains ongoing.

Hollow Microneedles

Hollow microneedles feature a central lumen or bore that enables pressure-driven flow of liquid formulations into the skin, analogous to a microscopic hypodermic needle. This design offers the theoretical advantage of delivering larger volumes (hundreds of microliters to milliliters) compared to solid or coated microneedles, making hollow microneedles suitable for peptides requiring higher doses.

Design and Fabrication: Hollow microneedles have been fabricated from silicon (using deep reactive ion etching), metals (using laser drilling and electroplating), glass (using micropipette pulling techniques), and polymers (using micromolding with insert pins). The bore diameter, typically 10–100 μm, determines the flow rate and the risk of clogging. Single hollow microneedles (as used in the Nanopass MicronJet device) and arrays of multiple hollow microneedles have been developed.

Infusion Characteristics: Unlike subcutaneous injection with a conventional hypodermic needle, hollow microneedles deliver into the superficial dermis or epidermis, where the tissue hydraulic resistance is higher and the fluid capacity is more limited. Infusion rates are typically limited to 0.1–1 mL/min for single microneedles and up to several mL/min for multi-needle arrays. Back-pressure monitoring and controlled infusion systems can prevent excessive pressure that might cause tissue damage or retrograde leakage.

Clinical Evidence: The Nanopass MicronJet, a single-use hollow microneedle device for intradermal injection, has received regulatory clearance and has been investigated for influenza vaccination, insulin delivery, and local anesthetic administration. Studies have demonstrated that intradermal insulin delivery via hollow microneedle produces more rapid systemic absorption (Tmax ~20 min vs. ~60 min for subcutaneous) and more physiological pharmacokinetics than conventional subcutaneous injection.

Iontophoresis

Iontophoresis uses a low-level electric current (typically 0.1–1.0 mA/cm²) to drive charged molecules through the skin. The technique has been employed clinically for decades—primarily for local drug delivery (lidocaine, dexamethasone, pilocarpine)—and has been extensively investigated for transdermal peptide delivery.

Physical Principles

Iontophoretic transport occurs through two primary mechanisms. Electromigration (also termed electrorepulsion) is the direct movement of charged ions in response to the applied electric field. Positively charged peptides (cations) are driven from the anode toward the cathode through the skin, while negatively charged peptides (anions) are driven from the cathode to the anode. The electromigration contribution to total flux is proportional to the peptide's charge, its electrophoretic mobility, and the applied current density.

Electroosmosis is the bulk flow of solvent (water) induced by the electric field. At physiological pH, the skin carries a net negative charge due to ionized carboxyl groups on structural proteins and lipids. This fixed negative charge creates an electrical double layer with a net excess of mobile cations in the skin pores. When an electric field is applied, the preferential movement of these cations toward the cathode drags solvent along, producing a net convective flow from anode to cathode. Electroosmosis enhances the transport of neutral and positively charged molecules, while negatively charged molecules experience opposing electromigration and electroosmotic forces.

For peptide delivery, the net transport direction depends on the relative magnitudes of electromigration and electroosmosis. Highly charged peptides are dominated by electromigration, while weakly charged or neutral peptides are transported primarily by electroosmosis. The peptide's isoelectric point (pI) relative to the pH of the formulation and the skin determines the net charge and thus the dominant transport mechanism.

Peptide-Specific Considerations

Peptide delivery by iontophoresis presents several unique challenges. Peptides are typically polyelectrolytes with multiple ionizable groups, and their net charge varies with pH. The formulation pH must be selected to optimize the net charge for electromigration while maintaining peptide stability and solubility.

Electrochemical reactions at the electrodes produce pH changes that can compromise peptide stability: water electrolysis at the anode generates H⁺ (decreasing pH), while at the cathode OH⁻ is produced (increasing pH). Buffer systems in the electrode compartments are essential but must be designed to maintain appropriate pH without introducing competing ions that reduce current efficiency for peptide transport.

Peptide adsorption to skin components, particularly at the low concentrations used in iontophoretic delivery, can significantly reduce the effective flux. Electrostatic interactions between charged peptides and oppositely charged skin components can result in peptide binding within the skin rather than transport to the systemic circulation.

Clinical Applications

Iontophoretic delivery of peptides has been investigated most extensively for:

LHRH Agonists: Leuprolide and nafarelin have been studied with iontophoretic delivery for prostate cancer, endometriosis, and precocious puberty. Clinical studies have demonstrated that iontophoretic leuprolide delivery produces pulsatile LHRH agonist profiles that effectively suppress gonadal steroid production.

Calcitonin: Salmon calcitonin iontophoresis has been investigated for osteoporosis and Paget's disease. Preclinical studies in rats and rabbits have demonstrated that iontophoretic calcitonin delivery produces hypocalcemic effects comparable to subcutaneous injection.

Insulin: Iontophoretic insulin delivery has been extensively studied, with clinical studies demonstrating that iontophoresis can produce rapid systemic insulin absorption with corresponding glucose-lowering effects. However, the current density required for therapeutic insulin delivery (typically 0.4–1.0 mA/cm²) approaches the threshold for skin irritation, and the delivered dose is limited by the available skin area.

Fentanyl Analogs: While not peptides, the iontophoretic fentanyl system (IONSYS®) provides a regulatory precedent for iontophoretic peptide delivery, demonstrating that iontophoretic devices can achieve regulatory approval with appropriate safety and efficacy data.

Sonophoresis

Sonophoresis employs ultrasound energy, typically in the low-frequency range (20–100 kHz), to enhance transdermal drug transport. The technique has been investigated for a wide range of drugs, including peptides.

Mechanisms of Enhancement

Low-frequency sonophoresis enhances skin permeability primarily through acoustic cavitation—the formation, oscillation, and collapse of gas bubbles in the coupling medium and within the skin itself. Cavitation produces several effects relevant to transdermal peptide delivery:

Microstreaming: Oscillating cavitation bubbles generate localized fluid flows (microstreaming) that can mechanically disrupt the lipid bilayers of the stratum corneum, increasing permeability. Microstreaming velocities near oscillating bubbles can reach meters per second, producing shear forces sufficient to alter lipid organization.

Microjet Formation: Asymmetric bubble collapse near a surface generates high-velocity microjets that can physically penetrate the stratum corneum, creating localized transport pathways. Microjet velocities can exceed 100 m/s, producing transient pores in the lipid matrix.

Thermal Effects: Acoustic energy absorption produces localized heating, which increases lipid bilayer fluidity and molecular diffusivity. While modest—typically 2–5°C for clinical sonophoresis parameters—this heating contributes additively to cavitation effects.

Low-frequency ultrasound (20–100 kHz) is more effective than therapeutic (1–3 MHz) or diagnostic (>3 MHz) ultrasound for transdermal delivery because cavitation intensity increases as frequency decreases. The lower frequency also provides greater penetration depth in tissue.

Peptide Delivery Applications

Sonophoretic peptide delivery has been investigated in preclinical models for several therapeutic peptides. Studies of sonophoretic insulin delivery in rats and pigs have demonstrated significant reductions in blood glucose, with effects proportional to the applied ultrasound energy. Low-frequency sonophoresis (20 kHz) has been applied to deliver low-molecular-weight heparin through pig skin in vitro, achieving flux rates sufficient for therapeutic anticoagulation.

Sonophoretic delivery of vaccines—including tetanus toxoid, influenza antigens, and hepatitis B surface antigen—has been investigated as a needle-free immunization strategy. The combination of barrier disruption and the potential for adjuvant effects from ultrasound-induced tissue responses makes sonophoresis particularly interesting for transcutaneous immunization.

Limitations

Despite promising preclinical data, sonophoretic peptide delivery has not progressed to late-stage clinical development. Several challenges have limited translation: the complexity and cost of ultrasound devices relative to other enhancement technologies; variable enhancement depending on skin site, hydration, and thickness; the potential for thermal damage at the ultrasound intensities required for adequate enhancement; and the modest enhancement factors achieved for larger peptides (>3,000 Da). Sonophoresis may find niche applications for specific peptide-skin combinations where other technologies are unsuitable.

Thermal Ablation

Thermal ablation creates localized, controlled thermal damage to the stratum corneum, generating micrometer-scale pores through which peptides can diffuse into the viable epidermis. The technique uses brief (microsecond to millisecond) pulses of thermal energy to vaporize stratum corneum tissue without damaging the deeper viable epidermis or dermis.

Technology Platforms

Radiofrequency (RF) Ablation: RF ablation uses alternating electrical current at radiofrequencies (typically 100–500 kHz) to generate resistive heating in tissue. Microfabricated electrode arrays create arrays of microchannels with precisely controlled depth. The ViaDerm system (developed by TransPharma Medical) used RF microchannel ablation followed by a drug patch for peptide delivery and was evaluated in clinical studies for PTH(1-34) delivery.

Laser Ablation: Erbium:yttrium-aluminum-garnet (Er:YAG) lasers operating at 2,940 nm, which corresponds to a major water absorption peak, can ablate stratum corneum tissue with micrometer precision. The short optical penetration depth at this wavelength (~1 μm) confines ablation to the superficial skin layers. Fractional laser systems create arrays of microscopic thermal damage zones surrounded by intact tissue, facilitating rapid healing while providing transport pathways for drug delivery.

Thermal Microporation: Devices that apply brief pulses of thermal energy through an array of electrically heated microfilaments have been developed for creating transdermal microchannels. The PassPort system (developed by Altea Therapeutics) used thermal microporation followed by a patch for transdermal delivery.

Peptide-Specific Applications

Thermal ablation has been most extensively investigated for transdermal peptide delivery of PTH(1-34) for osteoporosis. The ViaDerm system demonstrated that RF microchannel ablation pretreatment followed by PTH(1-34) patch application produced pharmacokinetics similar to subcutaneous injection, with rapid absorption and appropriate elimination. Phase II clinical trials reported significant increases in bone mineral density comparable to daily subcutaneous teriparatide injections.

Thermal ablation has also been investigated for insulin delivery, with preclinical and early clinical studies demonstrating that laser or RF microporation can enable insulin absorption with corresponding glucose-lowering effects. The rapid microchannel resealing (typically within 24–48 hours) is advantageous for therapeutic peptides requiring once-daily or intermittent dosing.

Advantages and Limitations

Thermal ablation offers rapid, reliable, and highly localized disruption of the stratum corneum, with enhancement factors that can exceed those achieved with chemical enhancers. The depth of ablation can be precisely controlled, limiting potential damage to viable tissue. However, the need for an electrical or laser device adds cost and complexity. The two-step administration process (ablation followed by patch application) is less convenient than integrated systems. And the potential for thermal damage to peptide drugs if ablation and drug application are not temporally separated must be considered.

Chemical Penetration Enhancers

Chemical penetration enhancers (CPEs) are compounds that interact with stratum corneum components to increase permeability without physical disruption. While CPEs alone rarely achieve sufficient enhancement for peptide delivery, they are valuable components of combination enhancement strategies.

Classes of Chemical Enhancers

Fatty Acids and Alcohols: Oleic acid, linoleic acid, and medium-chain alcohols (ethanol, isopropyl alcohol) disrupt stratum corneum lipid packing through insertion into lipid bilayers, increasing fluidity. Oleic acid is particularly effective, producing phase separation within stratum corneum lipids when applied at sufficient concentrations.

Surfactants: Anionic surfactants (sodium lauryl sulfate), cationic surfactants (cetyltrimethylammonium bromide), and nonionic surfactants (polysorbates, poloxamers) enhance permeability through lipid extraction, protein denaturation, and membrane fluidization. The enhancement potency generally follows the order anionic > cationic > nonionic, but skin irritation potential follows the same order.

Terpenes: Monoterpenes (menthol, limonene, eucalyptol) and sesquiterpenes enhance permeability through lipid bilayer disruption. Terpenes offer the advantage of generally low toxicity and favorable sensory properties (many are fragrant), but enhancement factors are typically modest (2–10 fold).

Sulfoxides: Dimethyl sulfoxide (DMSO) is a potent enhancer that interacts with stratum corneum lipids and proteins, but its clinical use is limited by odor, skin irritation at higher concentrations, and concerns about facilitating the entry of environmental contaminants.

Pyrrolidones: N-methyl-2-pyrrolidone (NMP) and 2-pyrrolidone enhance permeability through effects on both the lipid and protein components of the stratum corneum. NMP has been used in several transdermal products as a co-solvent and enhancer.

Peptide-Specific Enhancers: Certain peptides themselves can function as permeation enhancers. Polyarginine (particularly R7–R11) and other cell-penetrating peptides have been shown to enhance transdermal transport of co-administered macromolecules, possibly through transient disruption of intercellular lipid organization. The mechanism remains incompletely characterized but may involve peptide-lipid interactions and transient pore formation.

Integration with Physical Enhancement Technologies

The most promising application of chemical enhancers for peptide delivery is in combination with physical enhancement technologies. Chemical enhancers can extend the lifetime of microneedle-created microchannels by slowing the barrier recovery process. CPE-impregnated microneedles combine the mechanical disruption of microneedles with the lipid-disrupting effects of chemical enhancers. And chemical enhancer-containing formulations applied to iontophoretically treated skin can synergistically increase flux beyond the sum of individual effects.

Research Evidence

Delivery Technology Peptide Cargo Study Phase Key Finding Reference
Solid microneedle pretreatment Insulin Preclinical (rat) Microneedle-treated skin delivered insulin with pharmacodynamics approaching SC injection Martanto W, et al. Pharm Res. 2004
Coated microneedle patch PTH(1-34) Phase III Rapid absorption (Tmax ~8 min); BMD increases comparable to SC teriparatide Daddona PE, et al. Pharm Res. 2011
Dissolving microneedle patch Influenza vaccine Phase I Immunogenicity comparable to IM injection; favorable local tolerability Rouphael NG, et al. Lancet. 2017
Hollow microneedle (MicronJet) Insulin Phase II Faster absorption (Tmax 20 vs 60 min SC); more physiological PK profile Pettis RJ, et al. Diabetes Technol Ther. 2011
Hollow microneedle Influenza vaccine Approved (device) Intradermal delivery; dose-sparing potential Van Damme P, et al. Vaccine. 2009
Iontophoresis Calcitonin Preclinical (rat, rabbit) Hypocalcemic effect comparable to SC injection Nakamura K, et al. J Control Release. 2012
Iontophoresis Leuprolide Phase I/II Gonadal steroid suppression maintained with iontophoretic delivery Kochhar JS, et al. Expert Opin Drug Deliv. 2013
Low-frequency sonophoresis Insulin Preclinical (rat, pig) Dose-dependent glucose reduction; enhancement factor 50–100× Mitragotri S, et al. Science. 1995
RF thermal ablation (ViaDerm) PTH(1-34) Phase II Pharmacokinetics similar to SC injection; BMD improvement Levin G, et al. Diabetes Technol Ther. 2008
Laser ablation (Er:YAG) Insulin Preclinical (rat) Microporation enabled rapid insulin absorption Lee WR, et al. J Invest Dermatol. 2008
Chemical enhancer (polyarginine) Protein antigens Preclinical (mouse) Enhanced transcutaneous immunization with co-administered antigen Nasrollahi SA, et al. Int J Pharm. 2012
Combination (microneedle + iontophoresis) Low MW model peptides Preclinical (in vitro) Synergistic enhancement; >1000× permeability increase Donnelly RF, et al. Pharm Res. 2010

Current Understanding

The current state of transdermal peptide delivery reflects significant technological achievement that has not yet translated into widespread clinical products. Several key insights have emerged:

Microneedles are the leading platform for transdermal peptide delivery, with coated and dissolving microneedle technologies advancing furthest in clinical development. The ability to engineer microneedles from biocompatible, water-soluble materials with controlled dissolution kinetics has addressed many of the early limitations of the technology. However, the dose capacity of microneedle patches (typically <1 mg per patch) limits their application to potent peptides with low dose requirements.

Combination strategies show the greatest promise. The convergence of multiple enhancement modalities—microneedle pretreatment with iontophoretic driving, sonophoresis with chemical enhancers—can achieve synergistic effects that exceed the capabilities of any single technology. The challenge lies in engineering practical, patient-acceptable combination delivery systems.

Peptide physicochemical properties critically influence transdermal deliverability. Small, hydrophobic, and uncharged peptides are more amenable to passive or mildly enhanced transdermal delivery. Large, highly charged, hydrophilic peptides require more aggressive enhancement and are less likely to achieve therapeutic flux through practical skin areas. Structure-transport relationship studies are beginning to provide predictive frameworks for peptide transdermal deliverability.

Regulatory pathways are evolving. While individual technology components (microneedle devices, iontophoretic systems) have achieved regulatory clearance, the combination of a novel delivery device with a peptide drug creates a drug-device combination product requiring demonstration of both drug efficacy and device performance. Regulatory expectations for transdermal peptide products continue to be refined through interactions between developers and agencies.

Future Research Directions

  • High-capacity microneedle arrays with increased drug loading per unit area through advanced polymer engineering, multilayered microneedle structures, and hybrid solid-reservoir designs enabling milligram-scale peptide delivery

  • Self-administrable, fully integrated microneedle patch systems combining microneedle array, drug reservoir, and adhesive backing in a product format requiring minimal user instruction

  • Responsive and smart microneedle systems that release peptides in response to physiological stimuli (glucose-responsive insulin microneedles, for example) to approximate physiological hormone secretion patterns

  • Long-wear microneedle systems engineered for sustained peptide delivery over days to weeks from a single application, potentially replacing daily injections for chronic peptide therapies

  • Combination device platforms integrating microneedles with iontophoresis or sonophoresis in patient-friendly form factors, exploiting the synergistic enhancement of combined technologies

  • Computational skin transport models incorporating peptide physicochemical properties, microneedle geometry, skin microstructure, and device parameters to predict transdermal flux and guide formulation optimization

  • Biologics delivery extending beyond peptides to monoclonal antibodies, fusion proteins, and nucleic acid therapeutics through appropriately engineered microneedle and physical enhancement systems

  • Pediatric and elderly applications addressing specific needs: needle-free vaccination for children, simplified administration for elderly patients with reduced injection self-administration capability

  • Personalized transdermal delivery through patient-specific microneedle array designs based on skin thickness, hydration, and vascularization, potentially enabled by 3D printing technologies

  • Transdermal peptide delivery for central nervous system targets exploiting the potential for direct delivery to the cerebrospinal fluid via the nasal-olfactory route or through specially engineered transdermal systems

Frequently Asked Questions

Why can't peptides be delivered through the skin using conventional transdermal patches?

The stratum corneum, the outermost 10–20 μm of human skin, functions as an extremely effective barrier against the entry of foreign molecules. Its "brick and mortar" structure—corneocytes embedded in a continuous lipid matrix of ceramides, cholesterol, and free fatty acids—has an effective permeability cutoff at approximately 500 Da molecular weight. Most therapeutic peptides exceed 1,000 Da, contain numerous hydrogen bond donors and acceptors, and are highly hydrophilic—all characteristics that effectively exclude them from passive transdermal permeation. Without active technologies that transiently disrupt or bypass the stratum corneum, the flux of therapeutic peptides through intact skin is negligible.

How do dissolving microneedles compare to coated microneedles for peptide delivery?

Dissolving microneedles incorporate the peptide throughout a water-soluble polymer matrix that completely dissolves upon skin insertion, while coated microneedles deposit a thin peptide coating on the surface of solid microneedles. Dissolving microneedles can achieve higher drug loading (potentially 1–5 mg per patch vs. 0.1–1 mg for coated), generate no sharps waste, and eliminate the risk of needle tip fracture in skin. However, dissolving microneedles can be mechanically weaker (potentially compromising insertion), expose peptides to a drying step that may induce aggregation, and dissolve more slowly than coatings. Coated microneedles offer faster dissolution and drug release, established fabrication on metal or silicon substrates with superior mechanical properties, but are limited in drug loading capacity. The choice between technologies depends on the specific peptide dose, physicochemical properties, and stability considerations. Researchers can explore peptide analytical specifications and stability data through the RPL Peptide Data Center.

What is the maximum dose that can be delivered transdermally using current microneedle technology?

Current coated microneedle patches can typically deliver 0.1–1 mg of peptide per patch (approximately 1–10 cm² area). Dissolving microneedle patches can deliver 1–5 mg per patch. Hollow microneedles with pumped liquid reservoirs can deliver hundreds of microliters to milliliters, potentially tens of milligrams, but at the cost of increased device complexity. The practical upper limit is determined by the microneedle array area (limited by skin sites suitable for patch application), the drug loading per unit area (limited by microneedle geometry and mechanical properties), and the dissolution or release rate (limited by skin interstitial fluid volume and turnover). For peptides requiring doses above approximately 10 mg, transdermal delivery through current microneedle technology remains challenging but not impossible with sufficiently large patch sizes or hollow microneedle infusion systems.

How does iontophoresis compare with microneedles for transdermal peptide delivery?

Iontophoresis and microneedles operate through fundamentally different mechanisms. Iontophoresis uses an electric field to drive charged molecules through existing transport pathways (hair follicles, sweat ducts, intercellular lipid domains) while also inducing electroosmotic solvent flow. Microneedles create new, larger transport pathways by physical penetration of the stratum corneum. Iontophoresis provides continuous, controllable delivery with the ability to modulate flux by adjusting current, but requires the peptide to be charged at the delivery pH and is subject to competition from other ions in the formulation. Microneedles are not dependent on peptide charge and can deliver neutral molecules, but provide a bolus-type delivery determined by the drug loading per patch. Combination approaches (microneedle pretreatment followed by iontophoretic driving) have demonstrated synergistic enhancement, with microneedles creating the transport pathways and iontophoresis providing the driving force for sustained delivery.

Are microneedle patches painful?

Microneedles are designed to be painless, and this is one of their most significant advantages over conventional hypodermic needles. The microneedle length (typically 50–900 μm) is calibrated to penetrate the stratum corneum and viable epidermis without reaching the dermal nerve endings (located approximately 500–1,000 μm below the skin surface) or dermal blood vessels. Clinical studies consistently report that microneedle application produces minimal or no pain, with pain scores typically 1 or less on a 10-point visual analog scale, compared to scores of 3–5 for conventional hypodermic injections. Some patients report a mild pressure or tapping sensation during microneedle application, but the absence of pain is a defining characteristic of properly designed microneedle systems.

What are the skin safety concerns with repeated microneedle application?

Microneedle application creates transient microchannels that typically reseal within 24–72 hours through normal epidermal repair processes. Repeated application at the same skin site has been studied for up to several weeks in clinical trials. While mild, transient erythema (redness) is common immediately after application, resolving within hours, more significant adverse effects (infection, scarring, hyperpigmentation) are rare. The key safety consideration is maintaining aseptic application technique, as microchannels theoretically create portals for microbial entry. However, the rapid resealing kinetics and the intrinsic antimicrobial properties of skin limit infection risk. Long-term repeated application (>1 year) at the same site requires further study, and clinical protocols typically recommend site rotation similar to insulin injection site rotation.

Can sonophoresis deliver therapeutic peptides effectively?

Sonophoresis, particularly low-frequency sonophoresis (20–100 kHz), has demonstrated the ability to enhance transdermal transport of peptides including insulin, low-molecular-weight heparin, and various vaccine antigens in preclinical models. Enhancement factors of 50–1,000× have been reported for small to medium peptides. However, sonophoresis has not progressed to late-stage clinical development for peptide therapeutics. The primary limitations include the complexity and cost of ultrasound devices, variable enhancement depending on skin characteristics, the potential for thermal tissue effects at the intensities required for adequate enhancement, and the lower enhancement factors achieved for larger peptides. Sonophoresis may find roles in specific applications—transcutaneous immunization is particularly promising given the lower dose requirements and the potential for ultrasound-induced adjuvant effects—but is unlikely to become a broadly used platform for therapeutic peptide delivery in the near term.

What chemical enhancers are most effective for transdermal peptide delivery?

No single chemical permeation enhancer achieves sufficient enhancement for therapeutic transdermal peptide delivery when used alone. The most effective enhancers for peptides, based on preclinical studies, include cell-penetrating peptides (particularly polyarginine R7–R11), which can produce enhancement factors of 10–50× for co-administered macromolecules. Fatty acids (oleic acid at 5–10%) and terpenes (menthol, limonene) produce modest enhancement (2–10×). Combinations of enhancers from different mechanistic classes can produce synergistic effects, and integration with physical enhancement technologies (microneedles, iontophoresis) is the most promising approach. The ideal enhancer combination for a given peptide depends on the peptide's physicochemical properties and the chosen physical enhancement modality.

What peptide characteristics favor transdermal delivery?

Peptides most amenable to transdermal delivery share several characteristics: low molecular weight (ideally <2,000 Da), moderate lipophilicity (logP 1–3), low charge density at physiological pH, high potency (allowing therapeutic effect at low dose), and good chemical stability in aqueous formulations. Cyclic peptides may exhibit enhanced transdermal permeability compared to linear peptides of similar molecular weight due to reduced hydrogen bonding capacity. Peptides containing basic amino acid residues (arginine, lysine) may benefit from iontophoretic driving at pH below their pI. For microneedle delivery, rapid dissolution kinetics and compatibility with concentrated formulations are favorable. Comprehensive peptide characterization data, including HPLC purity profiles and mass spectrometry confirmation, are available through the RPL Peptide Data Center to support transdermal formulation development.

Are there any approved transdermal peptide products on the market?

As of 2026, no transdermal peptide therapeutic has achieved broad FDA or EMA marketing authorization. However, several products and devices have achieved specific regulatory clearances. The MicronJet hollow microneedle device has regulatory clearance for intradermal injection and has been used with approved drug products. Several microneedle-based vaccine patches have completed Phase I/II clinical trials with encouraging results. The ZP-PTH coated microneedle patch for parathyroid hormone delivery received a Complete Response Letter from the FDA in 2021 citing manufacturing concerns; the technology has been acquired by Elixir Medical for further development. The field is advancing rapidly, and the first regulatory approvals for transdermal peptide products are anticipated within the next few years. Researchers interested in the latest transdermal delivery technologies can monitor developments through [RPL Peptide](https://rplpeptides.com).

!!! info "" **About RPL Peptide:** [RPL Peptide](https://rplpeptides.com) is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers developing transdermal peptide delivery systems requiring certified reference materials, visit [rplpeptides.com](https://rplpeptides.com) or explore detailed molecular data at the [RPL Peptide Data Center](https://data.rplpeptides.com).

What Is Established

  • Microneedles reliably breach the stratum corneum without reaching nerve endings or dermal vessels: application is characteristically low-pain, and microchannels reseal within 24–72 hours.
  • Both microneedle and iontophoretic routes have delivered peptide pharmacodynamics comparable to subcutaneous injection in early human studies — PTH(1-34) patches and intradermal insulin exemplify this.
  • Peptide properties constrain feasibility: lower molecular weight, moderate lipophilicity, lower charge density, and high potency favor success; large hydrophilic peptides remain the hardest cases.

What Remains Uncertain

  • Dose ceilings and long-term skin safety of repeated application; only limited multi-week data exist, and multi-year exposure is unstudied.
  • Performance predictability across skin sites, hydration states, and individuals — device parameters and skin variability interact in ways not fully modeled.
  • Whether regulatory pathways for drug–device combination products will coalesce fast enough to reward current candidates.

Research Gaps

  • Structure–transport relationships for peptides remain incompletely quantitative; deliverability frameworks are improving but not yet reliable design rules.
  • Computational skin-transport models that integrate device geometry, skin microstructure, and peptide properties are not yet validated standards.

Key References

  • Prausnitz MR, Langer R (2008). Transdermal drug delivery. Nature Biotechnology 26(11):1261–1268. doi:10.1038/nbt.1504 — The field-framing review of transdermal science, including microneedle and physical enhancement strategies.
  • Henry S, McAllister DV, Allen MG, Prausnitz MR (1998). Microfabricated microneedles: a novel approach to transdermal drug delivery. Journal of Pharmaceutical Sciences 87(8):922–925. doi:10.1021/js980042+ — First demonstration of microfabricated microneedles creating transdermal microchannels.
  • Daddona PE, Matriano JA, Mandema J, Maa YF (2011). Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharmaceutical Research 28(1):159–165. doi:10.1007/s11095-010-0192-9 — Human PK/PD validation of a coated microneedle peptide patch.
  • Rouphael NG, Paine M, Mosley R, et al. (2017). The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch: a phase 1 trial. The Lancet 390(10095):649–658. doi:10.1016/S0140-6736(17)30575-5 — Randomized phase 1 evidence for microneedle patch immunogenicity and tolerability.
  • Mitragotri S, Blankschtein D, Langer R (1995). Ultrasound-mediated transdermal protein delivery. Science 269(5225):850–853. doi:10.1126/science.7638603 — Foundational demonstration of sonophoretic macromolecule delivery.

References

  1. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology. 2008;26(11):1261–1268. doi:10.1038/nbt.1504
  2. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. Journal of Pharmaceutical Sciences. 1998;87(8):922–925. doi:10.1021/js980042+
  3. Donnelly RF, Singh TRR, Garland MJ, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Advanced Functional Materials. 2012;22(23):4879–4890. doi:10.1002/adfm.201200864
  4. Daddona PE, Matriano JA, Mandema J, Maa YF. Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharmaceutical Research. 2011;28(1):159–165. doi:10.1007/s11095-010-0192-9
  5. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews. 2012;64(14):1547–1568. doi:10.1016/j.addr.2012.04.005
  6. Rouphael NG, Paine M, Mosley R, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. The Lancet. 2017;390(10095):649–658. doi:10.1016/S0140-6736(17)30575-5
  7. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Advanced Drug Delivery Reviews. 2004;56(5):619–658. doi:10.1016/j.addr.2003.10.026
  8. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science. 1995;269(5225):850–853. doi:10.1126/science.7638603
  9. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. Journal of Controlled Release. 2011;152(3):330–348. doi:10.1016/j.jconrel.2011.01.006
  10. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials. 2008;29(13):2113–2124. doi:10.1016/j.biomaterials.2007.12.048
  11. Pettis RJ, Ginsberg B, Hirsch L, et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and lower postprandial glucose than conventional subcutaneous injection. Diabetes Technology and Therapeutics. 2011;13(4):435–442. doi:10.1089/dia.2010.0155
  12. Sintov AC, Krymberk I, Daniel D, Hannan T, Sohn Z, Levin G. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. Journal of Controlled Release. 2003;89(2):311–320. doi:10.1016/S0168-3659(03)00123-8
  13. Karande P, Mitragotri S. Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2009;1788(11):2362–2373. doi:10.1016/j.bbamem.2009.08.015
  14. Ita K. Transdermal delivery of drugs with microneedles—potential and challenges. Pharmaceutics. 2015;7(3):90–105. doi:10.3390/pharmaceutics7030090
  15. Waghule T, Singhvi G, Dubey SK, et al. Microneedles: a smart approach and increasing potential for transdermal drug delivery system. Biomedicine & Pharmacotherapy. 2019;109:1249–1258. doi:10.1016/j.biopha.2018.10.078

— Written by the RPL Scientific Editorial Team | Last updated August 2026

Related Articles: Oral Peptide Delivery Strategies | Peptide Bioavailability Strategies | Peptide Formulation Science | RPL Peptide | Peptide Research Data